{"id":"NCT00603239","sponsor":"AstraZeneca","briefTitle":"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin","officialTitle":"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2008-01-29","resultsPosted":"2010-09-02","lastUpdate":"2015-04-07"},"enrollment":165,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["Byetta"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Exenatide twice daily (BID)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess safety and efficacy of exenatide in combination with a thiazolidinedione (TZD) and a TZD plus metformin over 26 weeks in adult patients with type 2 diabetes who have not achieved adequate glycemic control.","primaryOutcome":{"measure":"Change in Glycosylated Hemoglobin (HbA1c)","timeFrame":"baseline and 26 weeks","effectByArm":[{"arm":"Exenatide Twice Daily (BID)","deltaMin":-0.84,"sd":0.2},{"arm":"Placebo","deltaMin":-0.1,"sd":0.23}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":25,"countries":["United States","Canada","Mexico","Romania","South Africa"]},"refs":{"pmids":["20977576","22913891"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":111},"commonTop":["Nausea","Vomiting"]}}